

INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)Applicant  
Ann Marie Schmidt, et al.Filing Date  
November 7, 2002Group  
1642

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CY	5 8 6 4 0 1 8	4/16/96	Morser et al.			
CY	5 5 8 5 3 4 4		Vlassara et al.			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation No
CY	WO 9 8 2 2 1 3 8	5/28/98	PCT			
CY	WO 9 7 3 9 1 2 1	10/23/97	PCT			
CY	WO 9 7 3 9 1 2 5	10/23/97	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CY	Hori et al. 'The Receptor for Advanced Glycation Endproducts: Implications for the Development of Diabetic Vascular Disease. Fundam. Clin. Cardiol.' In: The Endothelium in Clinical Practice. January 1997, Chapter 11, pages 311-329 (Exhibit 1);
CY	Yan et al. Amyloid-beta Peptide- Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease. Proc. Natl. Acad. Sci. 13 May 1997, Vol. 94, No. 10, pages 5296-5301 (Exhibit 2);
CY	Schmidt et al. V-domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications. Circulation. 21 October 1997, Vol. 96, No. 8 Suppl., page I37 (Exhibit 3);
CY	Hori et al. The Receptor for Advanced Glycation Endproducts (RAGE) Is A Cell Surface Receptor for Amphoterin in the Developing Central Nervous System (CNS) to Promote Neurite Outgrowth. FASEB J. 1995, Vol. 9, No. 3, page A382 (Exhibit 4);

EXAMINER

Christopher Yaen

DATE CONSIDERED

9.9.03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

**U.S. Department of Commerce  
Patent and Trademark Office**

Serial N .  
09689,469

**Applicant**  
**Ann Marie Schmidt, et al.**

**Group  
1642**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

cy

International Search Report of International Application No.  
PCT/US99/08427, dated August 19, 1999 (Exhibit 5);

cy

Park, L., et al. (1998) "Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE)" Nature Medicine, 4:1025-1031;

cy

Vlassara, H., et al. (1995) "Identification of Galectin-2 as a high affinity binding protein for Advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex" Molecular Medicine, 1:634-646;

CY

Yan S-D, Chen X, Chen M, Zhu H, Roher A, Slattey T, Zhao L, Nagashima
M, Morser J, Migheli A, Nawroth P, Stern DM, Schmidt A-M: RAGE and
amyloid-beta peptide neurotoxicity in Alzheimer's disease. <i>Nature</i>
1996;382:685-691.

RECEIVED  
NOV 14 2002  
TECH CENTER 1600/2900

Christopher Yaen

9.9.03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.